Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines - PubMed (original) (raw)
Comparative Study
. 1990 Jul 4;82(13):1113-8.
doi: 10.1093/jnci/82.13.1113.
Affiliations
- PMID: 2359137
- DOI: 10.1093/jnci/82.13.1113
Comparative Study
Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines
L V Rubinstein et al. J Natl Cancer Inst. 1990.
Abstract
The National Cancer Institute (NCI) is implementing a large-scale in vitro drug-screening program that requires a very efficient automated assay of drug effects on tumor cell viability or growth. Many laboratories worldwide have adopted a microculture assay based on metabolic reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). However, because of certain technical advantages to use of the protein-binding dye sulforhodamine B (SRB) in a large-scale screening application, a detailed comparison of data generated by each type of assay was undertaken. The MTT and SRB assays were each used to test 197 compounds, on simultaneous days, against up to 38 human tumor cell lines representing seven major tumor categories. On subsequent days, 38 compounds were retested with the SRB assay and 25 compounds were retested with the MTT assay. For each of these three comparisons, we tabulated the differences between the two assays in the ratios of test group values to control values (T/C) for cell survival; calculated correlation coefficients for various T/C ratios; and estimated the bivariate distribution of the values for IC50 (concentration of drug resulting in T/C values of 50%, or 50% growth inhibition) for the two assays. The results indicate that under the experimental conditions used and within the limits of the data analyses, the assays perform similarly. Because the SRB assay has practical advantages for large-scale screening, however, it has been adopted for routine use in the NCI in vitro antitumor screen.
Similar articles
- A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines.
Perez RP, Godwin AK, Handel LM, Hamilton TC. Perez RP, et al. Eur J Cancer. 1993;29A(3):395-9. doi: 10.1016/0959-8049(93)90394-u. Eur J Cancer. 1993. PMID: 8398340 - Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays.
van Tonder A, Joubert AM, Cromarty AD. van Tonder A, et al. BMC Res Notes. 2015 Feb 20;8:47. doi: 10.1186/s13104-015-1000-8. BMC Res Notes. 2015. PMID: 25884200 Free PMC article. - Evaluation of in vitro chemosensitivity using human lung cancer cell lines.
Kratzke RA, Kramer BS. Kratzke RA, et al. J Cell Biochem Suppl. 1996;24:160-4. doi: 10.1002/jcb.240630511. J Cell Biochem Suppl. 1996. PMID: 8806098 Review. - Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia.
Hayon T, Dvilansky A, Shpilberg O, Nathan I. Hayon T, et al. Leuk Lymphoma. 2003 Nov;44(11):1957-62. doi: 10.1080/1042819031000116607. Leuk Lymphoma. 2003. PMID: 14738150 Review.
Cited by
- 7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-ones Designed by a "Cut and Glue" Strategy Are Dual Aurora A/VEGF-R Kinase Inhibitors.
Karatas M, Chaikuad A, Berger B, Kubbutat MHG, Totzke F, Knapp S, Kunick C. Karatas M, et al. Molecules. 2021 Mar 14;26(6):1611. doi: 10.3390/molecules26061611. Molecules. 2021. PMID: 33799460 Free PMC article. - Microwave assisted synthesis and in vitro cytotoxicities of substituted (Z)-2-amino-5-(1-benzyl-1H-indol-3-yl)methylene-1-methyl-1H-imidazol-4(5H)-ones against human tumor cell lines.
Penthala NR, Yerramreddy TR, Crooks PA. Penthala NR, et al. Bioorg Med Chem Lett. 2010 Jan 15;20(2):591-3. doi: 10.1016/j.bmcl.2009.11.083. Epub 2009 Nov 22. Bioorg Med Chem Lett. 2010. PMID: 20006496 Free PMC article. - Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. Koul D, et al. Neuro Oncol. 2010 Jun;12(6):559-69. doi: 10.1093/neuonc/nop058. Epub 2010 Feb 15. Neuro Oncol. 2010. PMID: 20156803 Free PMC article. - Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.
Scott J, Dorr RT, Samulitis B, Landowski TH. Scott J, et al. Cancer Chemother Pharmacol. 2007 May;59(6):749-57. doi: 10.1007/s00280-006-0329-z. Epub 2007 Feb 28. Cancer Chemother Pharmacol. 2007. PMID: 17333195 Free PMC article. - Parabolic growth patterns in 96-well plate cell growth experiments.
Faessel HM, Levasseur LM, Slocum HK, Greco WR. Faessel HM, et al. In Vitro Cell Dev Biol Anim. 1999 May;35(5):270-8. doi: 10.1007/s11626-999-0071-z. In Vitro Cell Dev Biol Anim. 1999. PMID: 10475273
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources